The classic Philadelphia chromosome-negativemyeloproliferative neoplasms (MPN) consist ofmyelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood cells. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for MPN were developed as a result of meetings convened by a multidisciplinary panel with expertise in MPN, with the goal of providing recommendations for themanagement of MPN in adults. TheGuidelines include recommendations for the diagnostic workup, risk stratification, treatment, and supportive care strategies for the management of myelofibrosis, polycythemia vera, and essential thrombocythemia. Assessment of symptoms at baseline and monitoring of symptom status during the course of treatment is recommended for all patients. This article focuses on the recommendations as outlined in the NCCN Guidelines for the diagnosis of MPN and the risk stratification, management, and supportive care relevant to MF.
|Original language||English (US)|
|Number of pages||30|
|Journal||JNCCN Journal of the National Comprehensive Cancer Network|
|State||Published - Sep 2022|
ASJC Scopus subject areas